Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy

被引:1
|
作者
Wan, Xiaofeng [1 ]
Chen, Chuanrong [2 ]
Zhan, Jianmin [1 ]
Ye, Shuke [1 ]
Li, Runsheng [1 ]
Shen, Ming [1 ]
机构
[1] Shanghai Inst Biomed & Pharmaceut Technol, Natl Hlth Commiss NHC, Key Lab Reprod Regulat, Shanghai, Peoples R China
[2] Yijishan Hosp, Dept Oncol, Wannan Med Coll, Wuhu, Peoples R China
基金
中国国家自然科学基金;
关键词
dendritic polylysine; siRNA delivery; tumor microenvironment sensitivity; drug resistance; triple-negative breast cancer; EXTRACELLULAR PH; RESISTANCE; AXL; SYSTEM; TUMORS;
D O I
10.3389/fbioe.2024.1415191
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Drug resistance is common in triple-negative breast cancer (TNBC) therapy. To identify a method to overcome chemotherapy resistance in TNBC cells, an siRNA targeting the AXL gene (siAXL), which can overcome drug resistance, was used in this study. A nanodelivery system was constructed to co-deliver siAXL and paclitaxel (PTX).Methods: A biodegradable and tumor microenvironment (TME)-sensitive mPEG-coated dendritic polylysine material (PDPLL) was synthesized. This material was used to construct single-molecule nanoparticles to co-deliver PTX and siAXL. The drug encapsulation and morphological properties of the nanoparticles (NPs) were characterized. The sensitivity of the NPs to the TME was evaluated in vitro with a dialysis method. The tumor-targeting effect of the PDPLL NPs was evaluated by fluorescence imaging and drug distribution evaluation in vivo. The ability to overcome drug resistance was evaluated using PTX-resistant 4T1 cells (4T1/PTX cells) in both in vitro and in vivo models.Results: PDPLL NPs had a particle size of 49.6 +/- 5.9 nm and a zeta potential of 7.87 +/- 0.68 mV. The PTX drug loading (DL)% was 2.59%. The siAXL DL was 2.5 mg PDPLL: 10 nmol siAXL. The release of PTX showed sustained release performance. The release of siAXL showed sensitivity for the TME. The NPs were stable in the plasma. The NPs promoted cell uptake by PTX-resistant 4T1 cells (4T1/PTX) and promoted tumor targeting and permeability in vivo. siAXL enhanced the toxicity and apoptosis efficiency of PTX in 4T1/PTX cells, as well as the cycle arrest efficiency caused by PTX. The NPs improved the above effects. In mouse 4T1/PTX orthotopic tumors, the NPs enhanced the sensitization of PTX to siAXL.Conclusion: The PDPLL NP co-delivery system possesses good encapsulating potential not only for PTX but also for siRNA. It can enhance the tumor-targeting effect and overcome the drug resistance of 4T1/PTX both in vitro and in vivo. This system is a potential delivery system for RNAs.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer
    Han, Beom Seok
    Jung, Kyung Hee
    Lee, Ji Eun
    Yoon, Young-Chan
    Ko, Soyeon
    Park, Min Seok
    Lee, Yun Ji
    Kim, Sang Eun
    Cho, Ye Jin
    Lee, Pureunchowon
    Lim, Joo Han
    Jang, Eunsoo
    Kim, Hyunzu
    Hong, Soon-Sun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07): : 3083 - 3098
  • [32] Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro
    Garza-Morales, Rodolfo
    Gonzalez-Ramos, Roxana
    Chiba, Akiko
    Montes de Oca-Luna, Roberto
    McNally, Lacey R.
    McMasters, Kelly M.
    Gomez-Gutierrez, Jorge G.
    CANCERS, 2018, 10 (05)
  • [33] Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer
    Sai, Boya Manasa
    Dinakar, Yirivinti Hayagreeva
    Kumar, Hitesh
    Jain, Rupshee
    Kesharwani, Sharyu
    Kesharwani, Siddharth S.
    Mudavath, Shyam lal
    Ramkishan, Ajmeer
    Jain, Vikas
    THERAPEUTIC DELIVERY, 2024, 15 (11) : 871 - 891
  • [34] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    Schmid, P.
    Adams, S.
    Rugo, H. S.
    Schneeweiss, A.
    Barrios, C. H.
    Iwata, H.
    Dieras, V.
    Hegg, R.
    Im, S. -A.
    Wright, G. Shaw
    Henschel, V.
    Molinero, L.
    Chui, S. Y.
    Funke, R.
    Husain, A.
    Winer, E. P.
    Loi, S.
    Emens, L. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22): : 2108 - 2121
  • [35] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    O'Sullivan, Hazel
    Collins, Dearbhaile
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 986 - 986
  • [36] Analysis of Paclitaxel-induced apoptosis in triple-negative breast cancer
    Nakajima, Wataru
    Kurita, Tomoko
    Naito, Zenya
    Takei, Hiroyuki
    Tanaka, Nobuyuki
    CANCER SCIENCE, 2018, 109 : 461 - 461
  • [37] Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
    Sezer, Gulay
    Caner, Armagan
    Onal, Muge Gulcihan
    Cumaoglu, Ahmet
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2022, 156 (01) : 70 - 76
  • [38] Platinum-based chemotherapy in triple-negative breast cancer
    Sirohi, B.
    Arnedos, M.
    Popat, S.
    Ashley, S.
    Nerurkar, A.
    Walsh, G.
    Johnston, S.
    Smith, I. E.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1847 - 1852
  • [39] Platinum-Based Chemotherapy in Triple-Negative Breast Cancer
    Villarreal-Garza, C.
    Bouganim, N.
    Khalaf, D.
    Clemons, M.
    Kassam, F.
    Enright, K.
    Verma, S.
    Myers, J.
    Dent, R.
    CANCER RESEARCH, 2011, 71
  • [40] Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer
    Isaac-Lam, Meden F.
    PHARMACEUTICALS, 2024, 17 (05)